ZGN 1061

Drug Profile

ZGN 1061

Alternative Names: ZGN-1061

Latest Information Update: 05 Aug 2016

Price : $50

At a glance

  • Originator Unknown
  • Developer Zafgen
  • Class Obesity therapies; Small molecules
  • Mechanism of Action Methionine aminopeptidase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Obesity

Most Recent Events

  • 09 Mar 2017 Zafgen plans a phase II trial for Type 2 diabetes mellitus and Obesity in Australia
  • 04 Aug 2016 Phase-I clinical trials in Obesity in USA (SC)
  • 19 Jul 2016 ZGN 1061 licensed to Zafgen worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top